News >

Zanubrutinib Continues to Show Encouraging Activity in Relapsed/Refractory MCL

Nichole Tucker
Published: Friday, Jul 19, 2019

Yuqin Song, MD, PhD, chief physician and deputy director of the Lymphoma Department at Peking University Cancer Hospital in Beijing, China

Yuqin Song, MD, PhD
The BTK inhibitor zanubrutinib (BGB-3111) continued to show promising activity in patients with relapsed/refractory mantle cell lymphoma (MCL), with an overall response rate (ORR) of 84.7%, according to updated phase II findings presented at the 15th International Conference on Malignant Lymphoma. 

In China, we have bendamustine, [which] just got approved by the CDA. [We] also have lenalidomide (Revlimid), [which is a good choice for frail patients]. We also have several different CAR T-cell therapy products in our center.
Song Y, Zhou K, Zou D et al. Zanubrutinib in Patients with Relapsed/Refractory Mantle Cell Lymphoma. Presented at: 15th International Conference on Malignant Lymphoma Palazzo dei Congressi; June 18-22, 2019; Lugano, Switzerland.

... to read the full story
To Read the Full Story

View Conference Coverage
Online CME Activities
TitleExpiration DateCME Credits
Clinical Practice Connections™: From Diagnosis to Emerging Immunotherapeutic Options: Understanding the Burden and Risks in Peanut AllergySep 28, 20191.0
Enduring CME activity from the School of Breast Oncology®: 2018 Mid-Year Video UpdateSep 28, 20192.0
Publication Bottom Border
Border Publication